Inhibikase Therapeutics, Inc. (IKT) AI Stock Analysis
IKT AI stock analysis summary
AI ResearchInhibikase Therapeutics, Inc. is a clinical-stage biotechnology firm developing treatments for Parkinson's disease and related conditions. Over the trailing twelve months, the company generated $1 in revenue with an EPS of -$0.43. Its balance sheet holds $159.0M in cash and short-term investments as of June 30, 2026, alongside a 5-year share count increase of 4051.2%.
- Market cap
- $230.2M
- Revenue (TTM)
- $1
- P/E
- —
- 1Y return
- 9.3% S&P 500 16.8%
- Avg. target
- $5.55 236.4% vs last close
Bull case
- The company holds $159.0M in cash and short-term investments as of June 30, 2026, with a current ratio of 15.82.
- Wall Street analysts set a mean price target of $5.55, which is 236.4% above the last closing price of $1.65.
- Institutional ownership is high at 89.7%, alongside 8 Strong Buy ratings from analysts.
Bear case
- Dilution has been severe, with the share count increasing by 4051.2% over a 5-year period.
- Revenue generation remains minimal at $1 for the trailing twelve months and a 5-year revenue CAGR of -42.2%.
- Short interest is elevated, with short percent of float standing at 21.7%.
What Inhibikase Therapeutics does
Inhibikase Therapeutics, Inc. is an Atlanta, Georgia-based clinical-stage pharmaceutical company focused on therapeutics for Parkinson's disease and related disorders. Its core pipeline candidate is IkT-148009, a small molecule inhibitor targeting Abelson tyrosine kinase to treat Parkinson's disease and gastrointestinal tract conditions. The company is also developing IkT-001Pro, a prodrug of imatinib mesylate designed for stable phase chronic myelogenous leukemia. Founded in 2008, the company collaborates with institutions including Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University, while partnering with Sphaera Pharma Pte. Ltd. to support research and clinical development.
Growth and profitability
Inhibikase recorded trailing twelve-month revenue of $1, with quarterly revenue falling 100.0% year-over-year in the period ended June 30, 2026. Annual revenue has been volatile, moving from $1.1M in FY2019 to $698,468 in FY2020, $3.1M in FY2021, $123,440 in FY2022, and $260,500 in FY2023, reflecting a 5-year revenue CAGR of -42.2%. Operating margin in FY2023 was -7712.0%, and net margin was -7304.8%. Net income has remained negative, recording -$5.7M in FY2019, -$2.9M in FY2020, -$14.8M in FY2021, -$18.1M in FY2022, and -$19.0M in FY2023. TTM EPS is -$0.43.
Balance sheet and cash flow
As of June 30, 2026, Inhibikase held $159.0M in cash and short-term investments, with total assets of $163.6M and shareholders' equity of $153.3M. The company reported a current ratio of 15.82. Operating cash flow was -$18.1M in FY2023, matching free cash flow of -$18.1M. In FY2025, capital expenditures totaled $13,396. Financing activity contributed to a 5-year share count change of 4051.2%.
Valuation and performance
At a share price of $1.65, Inhibikase has a market capitalization of $230.2M and an enterprise value of $212.4M. Its price-to-sales multiple is 10.4x, above the 4.1x median of its US-listed Healthcare peers. Its EV-to-EBITDA ratio is 0.3x, below the peer group median of 12.0x, while its price-to-book sits at 2.0x. Over the past year, the stock gained 9.3%, underperforming the 16.8% return of the S&P 500, while its 5-year return of -85.8% trailed the index return of 83.0%.
What analysts expect
Wall Street analysts hold 8 Strong Buy, 1 Buy, and 1 Hold ratings on the stock, with 0 Sell ratings. The mean price target is $5.55, representing an upside of 236.4% from the last close of $1.65. For the fiscal year ending December 31, 2026, estimated revenue is $187,500 with EPS of -$0.40. For the next fiscal year, 5 analysts expect revenue of $250,000 and EPS of -$0.42. Inhibikase beat EPS estimates in 1 of the trailing 4 quarters, and its next earnings date is November 13, 2026.
Key risks and what to watch
- Ongoing operational losses persisted with an FY2023 net loss of -$19.0M and negative free cash flow of -$18.1M.
- High dilution risk remains after common shares outstanding rose 4051.2% over five years.
- The stock has trailed broad markets with a 5-year return of -85.8% compared to 83.0% for the S&P 500.
- Clinical development demands heavy funding, with R&D expenses reaching $13.6M in FY2023.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this IKT AI stock analysis
This page is an AI-written research summary of Inhibikase Therapeutics, Inc. (IKT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: IKT income statement, IKT balance sheet, IKT key metrics, IKT analyst forecast, IKT chart. See the IKT stock overview for the latest quote and news.
IKT AI stock analysis FAQ
What is Inhibikase Therapeutics' main drug candidate?
Its lead pipeline asset is IkT-148009, an Abelson tyrosine kinase inhibitor being studied for Parkinson's disease and gastrointestinal tract conditions.
How much cash does Inhibikase have?
As of June 30, 2026, Inhibikase reported $159.0M in cash and short-term investments, supporting a current ratio of 15.82.
What are analysts forecasting for Inhibikase's revenue and earnings?
Analysts expect revenue of $187,500 and an EPS of -$0.40 for FY2026, followed by $250,000 in revenue and an EPS of -$0.42 for FY2027.
Does Inhibikase Therapeutics pay a dividend?
No, Inhibikase Therapeutics does not pay a dividend and has no dividend yield recorded.